Sirona Biochem Corp. attends BIO International the world’s largest gathering of Biotechnology companies May 18-21, 2009 in Atlanta, Georgia, USA.
As Canada’s first new publicly traded Biotech Company since 2007, Sirona Biochem will meet with major pharmaceutical companies in one on one meetings. The team will follow up with those companies that were met at BioPartnering North America (Feb 8-10, 2009) as well as establish discussions with numerous new potential partners. Meetings have been previously scheduled and the company is well prepared to explore all partnership opportunities.
Mark Senner, President said, “we are ready to explore partnering opportunities and believe that our drug discovery and development program is of great value to any potential partner. With a goal to add breakthrough treatment options for both diabetes and obesity, our program cannot be ignored.”
In addition to the partnering meetings, BIO International will provide a great forum to explore new opportunities for Sirona Biochem given that this is the world’s largest gathering of Biotechnology companies. Mark Senner President, Dr. Howard Verrico CEO and partner Dr. Géraldine Deliencourt-Godefroy President TFChem are attending the convention.
About Sirona Biochem Corp.
is an emerging biotech company dedicated to the discovery and development of innovative pharmaceutical products with current focus on treatments for Type II Diabetes and Obesity. Sirona Biochem Corp. has currently entered into a strategic partnership with TFChem which is a Drug Discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies in the therapeutic areas of cancer, pain, inflammatory disorders, and metabolic diseases. Through the research and development license, it is the intent to develop lead compounds in the SGLT Inhibitor class of drugs and develop partnerships with a major pharmaceutical company to continue ongoing development of the drugs through additional research, regulatory process and eventual commercialization of the identified lead compounds.
Sirona Biochem Corp. has corporate headquarters in Vancouver, British Columbia, Canada and is currently working in partnership with TFChem based in Rouen, France.
About BIO and the BIO International Convention
BIO was founded in 1993 and is based in Washington D.C. under the leadership of President and CEO, James C. Greenwood. Joshua Boger, PhD, President & CEO, Vertex Pharmaceuticals Incorporated, is the current Chairman. BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
The BIO International Convention showcases the many ways the biotechnology and life science industries work together to help heal, fuel, and feed the world. In 2009, more than 20,000 people from across the globe are expected to converge in Atlanta, Ga. on May 18-21 to attend the global event for biotechnology.